Received for publication June 27, 2006.
Revised September 24, 2006.
Accepted for publication September 25, 2006.

The effect of low pH on BCRP (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan and resveratrol in in vitro drug transport models

Abstract

Some cellular uptake systems for (anti)folates function optimally at acidic pH. We have tested whether this also applies to efflux from cells by Breast Cancer Resistance Protein (BCRP; ABCG2), which has been reported to transport folic acid, methotrexate, and methotrexate di- and triglutamate at physiological pH. Using Sf9-BCRP membrane vesicles, we showed that the ATP-dependent vesicular transport of 1 µM methotrexate by BCRP is 5-fold higher at pH 5.5 than at physiological pH. The transport of methotrexate was saturable at pH 5.5, with apparent K_m and V_max values of 1.3 ± 0.2 mM and 44 ± 2.5 nmoles/mg protein/min, but was linear with drug concentration at pH 7.3 up to 6 mM methotrexate. In contrast to recent reports, we did not detect transport of methotrexate diglutamate at physiological pH, but we did find transport at pH 5.5. We also found that 7-hydroxy- methotrexate, the major metabolite of methotrexate, is transported by BCRP both at physiological pH and (more efficiently) at low pH. The pH effect was also observed in intact BCRP-overexpressing cells: we found a 3-fold higher level of resistance to both methotrexate and the prototypical BCRP substrate mitoxantrone at pH 6.5 as at physiological pH. Furthermore, with MDCKII-BCRP monolayers, we found that resveratrol, which is a neutral compound at pH 7.4, is efficiently transported by BCRP at pH 6.0, whereas we did not detect active transport at pH 7.4. We conclude that BCRP transports substrate drugs more efficiently at low pH, independent of the dissociation status of the substrate.

Key words: MDR/p-Glycoprotein, Pharmacokinetics, metabolism and activation

This article has been cited by other articles:

				C. de Wolf, R. Jansen, H. Yamaguchi, M. de Haas, K. van de Wetering, J. Wijnholds, J. Beijnen, and P. Borst Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides Mol. Cancer Ther., September 1, 2008; 7(9): 3092 - 3102. [Abstract] [Full Text] [PDF]

				S. Marchetti, R. L. Oostendorp, D. Pluim, M. van Eijndhoven, O. van Tellingen, A. H. Schinkel, R. Versace, J. H. Beijnen, R. Mazzanti, and J. H. Schellens In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2 Mol. Cancer Ther., December 1, 2007; 6(12): 3307 - 3313. [Abstract] [Full Text] [PDF]

				H. Glavinas, E. Kis, A. Pal, R. Kovacs, M. Jani, E. Vagi, E. Molnar, S. Bansaghi, Z. Kele, T. Janaky, et al. ABCG2 (Breast Cancer Resistance Protein/Mitoxantrone Resistance-Associated Protein) ATPase Assay: A Useful Tool to Detect Drug-Transporter Interactions Drug Metab. Dispos., September 1, 2007; 35(9): 1533 - 1542. [Abstract] [Full Text] [PDF]